Literature DB >> 19264980

Update in cystic fibrosis 2008.

Felix Ratjen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264980     DOI: 10.1164/rccm.200812-1927UP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice.

Authors:  Caroline Rung Elsas; Elinor Langfelder Schwind; Laura Hercher; Michael J Smith; Kara Gardner Young
Journal:  J Genet Couns       Date:  2016-06-09       Impact factor: 2.537

Review 2.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

Review 3.  Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

Authors:  John Lam; Steven Vaughan; Michael D Parkins
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2013-11-13

4.  Clinical Outcomes Associated With Escherichia coli Infections in Adults With Cystic Fibrosis: A Cohort Study.

Authors:  B D Edwards; R Somayaji; J Greysson-Wong; C Izydorczyk; B Waddell; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  Open Forum Infect Dis       Date:  2019-11-18       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.